BR0213950A - Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas - Google Patents
Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicasInfo
- Publication number
- BR0213950A BR0213950A BR0213950-2A BR0213950A BR0213950A BR 0213950 A BR0213950 A BR 0213950A BR 0213950 A BR0213950 A BR 0213950A BR 0213950 A BR0213950 A BR 0213950A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- provides
- antigen
- diseases
- eosinofolic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
"ARRANJOS DE ANTìGENOS PARA O TRATAMENTO DE DOENçAS EOSINOFìLICAS ALéRGICAS". A presente invenção refere-se aos campos de biologia molecular, virologia, imunologia e medicina. A invenção proporciona uma composição compreendendo um arranjo ordenado e repetitivo de antígeno ou determinante antigênico e em particular um arranjo compreendendo uma proteína ou peptídeo de IL-5, IL-13 ou eotaxina. Mais especificamente, a invenção proporciona uma composição compreendendo uma partícula semelhante a vírus e pelo menos uma proteína ou peptídeo de IL-5, IL-13 e/ou eotaxina ligado à mesma. A invenção também proporciona um processo para a produção dos conjugados e dos arranjos ordenados e repetitivos, respectivamente. As composições da invenção são úteis na produção de vacinas para o tratamento de doenças alérgicas com um componente eosinofílico e como uma farmacina para impedir ou curar doenças alérgicas com um componente eosinofílico e para induzir eficientemente as respostas imunes, em particular as respostas de anticorpos. Além disso, as composições da invenção são particularmente úteis para induzir eficientemente as respostas imunes auto-específicas dentro do contexto indicado.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33104501P | 2001-11-07 | 2001-11-07 | |
US10/050,902 US7264810B2 (en) | 2001-01-19 | 2002-01-18 | Molecular antigen array |
PCT/IB2002/000166 WO2002056905A2 (en) | 2001-01-19 | 2002-01-21 | Molecular antigen array |
US39663602P | 2002-07-19 | 2002-07-19 | |
PCT/EP2002/012455 WO2003040164A2 (en) | 2001-11-07 | 2002-11-07 | Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0213950A true BR0213950A (pt) | 2004-08-24 |
Family
ID=27452010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0213950-2A BR0213950A (pt) | 2001-11-07 | 2002-11-07 | Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1443960B1 (pt) |
CN (1) | CN1321695C (pt) |
AT (1) | ATE419007T1 (pt) |
AU (1) | AU2002363382B2 (pt) |
BR (1) | BR0213950A (pt) |
CA (1) | CA2466492A1 (pt) |
DE (1) | DE60230656D1 (pt) |
DK (1) | DK1443960T3 (pt) |
ES (1) | ES2320638T3 (pt) |
HK (1) | HK1068355A1 (pt) |
IL (1) | IL161147A0 (pt) |
NZ (1) | NZ532516A (pt) |
PL (1) | PL369863A1 (pt) |
WO (1) | WO2003040164A2 (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
JP4516748B2 (ja) | 2001-09-14 | 2010-08-04 | サイトス バイオテクノロジー アーゲー | ウィルス様粒子中への免疫賦活物質のパッケージ化:調製法および使用法 |
AU2003225957A1 (en) * | 2002-03-25 | 2003-10-13 | Mercia Pharma, Llc | Treatment methods for eotaxin mediated inflammatory conditions |
BR0311800A (pt) * | 2002-07-19 | 2005-03-22 | Cytos Biotechnology Ag | Conjugados ghrelina-veìculo |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
AU2004308494B2 (en) | 2003-12-23 | 2010-03-18 | Genentech, Inc. | Novel anti-IL 13 antibodies and uses thereof |
EP1791870A1 (en) * | 2004-09-21 | 2007-06-06 | Cytos Biotechnology AG | Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
EP1830875A2 (en) * | 2004-12-13 | 2007-09-12 | Cytos Biotechnology AG | Il-15 antigen arrays and uses thereof |
US7767212B2 (en) * | 2005-03-18 | 2010-08-03 | Cytos Biotechnology Ag | CAT allergen conjugates and uses thereof |
RU2007147938A (ru) * | 2005-06-14 | 2009-07-20 | Цитос Биотехнологи Аг (Ch) | Конъюгаты антигенов и их применение |
KR20080047564A (ko) * | 2005-09-28 | 2008-05-29 | 사이토스 바이오테크놀로지 아게 | 인터루킨-1 컨쥬게이트 및 그의 용도 |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
NZ573622A (en) | 2006-06-12 | 2011-12-22 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
US10933129B2 (en) | 2011-07-29 | 2021-03-02 | Selecta Biosciences, Inc. | Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses |
MX2014007262A (es) | 2011-12-22 | 2014-08-01 | Hoffmann La Roche | Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso. |
EP4163633A1 (en) | 2013-09-13 | 2023-04-12 | F. Hoffmann-La Roche AG | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
NZ756749A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
RU2552929C1 (ru) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
MA40824A (fr) | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
CA3010975A1 (en) | 2015-01-15 | 2016-07-21 | University Of Copenhagen | Virus-like particle with efficient epitope display |
WO2017042212A1 (en) | 2015-09-08 | 2017-03-16 | Universität Zürich | Treatment of insect bite hypersensitivity |
WO2017071713A1 (en) | 2015-10-30 | 2017-05-04 | University Of Copenhagen | Virus like particle with efficient epitope display |
AU2018231413B2 (en) * | 2017-03-07 | 2024-01-04 | Evax Ag | Treatment of pruritus in horses |
EP3801604A1 (en) * | 2018-05-28 | 2021-04-14 | Evax AG | Treatment of urticaria |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69929232T2 (de) * | 1998-10-21 | 2006-08-31 | The United States Government As Represented By The Department Of Health And Human Services | Virusähnliche partikel zur induktion von autoantikörpern |
BR9915771A (pt) * | 1998-11-30 | 2001-12-26 | Cytos Biotechnology Ag | Apresentação molecular ordenada de antìgenos,processo de preparação e utilização |
EP1173573A1 (en) * | 1999-04-23 | 2002-01-23 | Pharmexa A/S | Method for down-regulating il5 activity |
-
2002
- 2002-11-07 NZ NZ532516A patent/NZ532516A/en not_active IP Right Cessation
- 2002-11-07 IL IL16114702A patent/IL161147A0/xx unknown
- 2002-11-07 AT AT02802656T patent/ATE419007T1/de not_active IP Right Cessation
- 2002-11-07 DK DK02802656T patent/DK1443960T3/da active
- 2002-11-07 BR BR0213950-2A patent/BR0213950A/pt not_active IP Right Cessation
- 2002-11-07 PL PL02369863A patent/PL369863A1/xx not_active Application Discontinuation
- 2002-11-07 WO PCT/EP2002/012455 patent/WO2003040164A2/en active IP Right Grant
- 2002-11-07 CA CA002466492A patent/CA2466492A1/en not_active Abandoned
- 2002-11-07 AU AU2002363382A patent/AU2002363382B2/en not_active Ceased
- 2002-11-07 DE DE60230656T patent/DE60230656D1/de not_active Expired - Lifetime
- 2002-11-07 EP EP02802656A patent/EP1443960B1/en not_active Expired - Lifetime
- 2002-11-07 CN CNB028218396A patent/CN1321695C/zh not_active Expired - Fee Related
- 2002-11-07 ES ES02802656T patent/ES2320638T3/es not_active Expired - Lifetime
-
2005
- 2005-01-20 HK HK05100515.1A patent/HK1068355A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE60230656D1 (de) | 2009-02-12 |
ATE419007T1 (de) | 2009-01-15 |
CN1321695C (zh) | 2007-06-20 |
DK1443960T3 (da) | 2009-03-23 |
ES2320638T3 (es) | 2009-05-27 |
IL161147A0 (en) | 2004-08-31 |
NZ532516A (en) | 2008-05-30 |
WO2003040164A3 (en) | 2003-10-23 |
EP1443960A2 (en) | 2004-08-11 |
EP1443960B1 (en) | 2008-12-31 |
WO2003040164A2 (en) | 2003-05-15 |
CA2466492A1 (en) | 2003-05-15 |
AU2002363382B2 (en) | 2007-07-19 |
PL369863A1 (en) | 2005-05-02 |
CN1558775A (zh) | 2004-12-29 |
HK1068355A1 (en) | 2005-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1068355A1 (en) | Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases | |
DE60329106D1 (de) | Ghrelin-träger-konjugate | |
DK1524994T3 (da) | Vaccinesammensætninger indeholdende amyloid beta 1-6-antigen-arrays | |
BRPI0206565A8 (pt) | Composições e seus usos, e processo de produção de um arranjo de antígeno ordenado e repetitivo, de ocorrência não-natural | |
WO2006063974A3 (en) | Il-15 antigen arrays and uses thereof | |
BR0213941A (pt) | Arranjos de antìgeno para o tratamento de doença óssea | |
NZ545048A (en) | Chimeric antigens for breaking host tolerance to foreign antigens | |
WO2006027300A3 (en) | Carrier conjugates of gnrh-peptides | |
MXPA04003901A (es) | Disposiciones de antigenos para el tratamiento de enfermedades eosinofilicas alergicas. | |
WO2003059386A3 (en) | Prion protein carrier-conjugates | |
MXPA04003900A (es) | Disposiciones de antigenos para el tratamiento de enfermedades oseas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |